PublisherDOIYearVolumeIssuePageTitleAuthor(s)Link
Cancer Research and Treatment10.4143/crt.2007.39.3.99200739399Oxaliplatin, 5-FU, Folinic Acid as First-line Palliative Chemotherapy in Elderly Patients with Metastatic or Recurrent Gastric CancerIn Sil Choi, Do-Youn Oh, Byoung-Su Kim, Keun-Wook Lee, Jee Hyun Kim, Jong-Seok Leehttp://www.e-crt.org/upload/pdf/crt-39-99.pdf, http://www.e-crt.org/upload/pdf/crt-39-99.pdf
BMC Cancer10.1186/1471-2407-14-5212014141Dose escalating study of cetuximab and 5-FU/folinic acid (FA)/oxaliplatin/irinotecan (FOLFOXIRI) in first line therapy of patients with metastatic colorectal cancerGunnar Folprecht, Susanne Hamann, Katharina Schütte, Tanja Trarbach, Jan Stoehlmacher-Williams, Gerhard Ehningerhttp://link.springer.com/content/pdf/10.1186/1471-2407-14-521.pdf, http://link.springer.com/article/10.1186/1471-2407-14-521/fulltext.html, http://link.springer.com/content/pdf/10.1186/1471-2407-14-521
Gastric Cancer10.1007/s10120-014-0405-82014183644-652Outcomes in elderly patients treated with a single-agent or combination regimen as first-line chemotherapy for recurrent or metastatic gastric cancerDer Sheng Sun, Eun Kyoung Jeon, Hye Sung Won, Ji Chan Park, Byoung Young Shim, Suk Young Park, Young Seon Hong, Hoon Kyo Kim, Yoon Ho Kohttp://link.springer.com/content/pdf/10.1007/s10120-014-0405-8.pdf, http://link.springer.com/article/10.1007/s10120-014-0405-8/fulltext.html, http://link.springer.com/content/pdf/10.1007/s10120-014-0405-8
BMC Cancer10.1186/1471-2407-6-125200661Weekly oxaliplatin, 5-fluorouracil and folinic acid (OXALF) as first-line chemotherapy for elderly patients with advanced gastric cancer: results of a phase II trialD Santini, F Graziano, V Catalano, M Di Seri, E Testa, AM Baldelli, P Giordani, A La Cesa, B Spalletta, B Vincenzi, A Russo, M Caraglia, V Virzi, S Cascinu, G Toninihttp://link.springer.com/content/pdf/10.1186/1471-2407-6-125.pdf, http://link.springer.com/article/10.1186/1471-2407-6-125/fulltext.html, http://link.springer.com/content/pdf/10.1186/1471-2407-6-125
European Journal of Cancer Supplements10.1016/s1359-6349(05)80894-8200532167598 ORAL Randomised comparison of 5-FU/folinic acid plus irinotecan (FOLFIRI) and irinotecan plus oxaliplatin (IROX) in first-line therapy of metastatic colorectal cancer (CRC): the fire-trialhttps://api.elsevier.com/content/article/PII:S1359634905808948?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1359634905808948?httpAccept=text/plain
European Journal of Cancer Supplements10.1016/s1359-6349(05)80938-3200532181-182642 POSTER Cetuximab plus oxaliplatin/5-fluorouracil (5-FU)/folinic acid (FA) (FOLFOX-4) for the epidermal growth factor receptor (EGFR)-expressing metastatic colorectal cancer (mCRC) in the first-line setting: a phase II studyhttps://api.elsevier.com/content/article/PII:S1359634905809383?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1359634905809383?httpAccept=text/plain
Cancer Chemotherapy and Pharmacology10.1007/s00280-010-1281-5201067141-48Sequential chemotherapy with dose-dense docetaxel, cisplatin, folinic acid and 5-fluorouracil (TCF-dd) followed by combination of oxaliplatin, folinic acid, 5-fluorouracil and irinotecan (COFFI) in metastatic gastric cancer: results of a phase II trialMatteo Dalla Chiesa, Gianluca Tomasello, Sebastiano Buti, Rodrigo Kraft Rovere, Matteo Brighenti, Silvia Lazzarelli, Gianvito Donati, Rodolfo Passalacquahttp://link.springer.com/content/pdf/10.1007/s00280-010-1281-5.pdf, http://link.springer.com/article/10.1007/s00280-010-1281-5/fulltext.html, http://link.springer.com/content/pdf/10.1007/s00280-010-1281-5
European Journal of Cancer Supplements10.1016/s1359-6349(05)80965-6200532190669 PUBLICATION Capecitabine and oxaliplatin (XELOX) as first-line treatment for elderly patients (pts) with advanced / metastatic colorectal cancer (MCRC)https://api.elsevier.com/content/article/PII:S1359634905809656?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1359634905809656?httpAccept=text/plain
BMC Cancer10.1186/1471-2407-14-3402014141FCGR2A and FCGR3A polymorphisms and clinical outcome in metastatic colorectal cancer patients treated with first-line 5-fluorouracil/folinic acid and oxaliplatin +/- cetuximabJanne B Kjersem, Eva Skovlund, Tone Ikdahl, Tormod Guren, Christian Kersten, Astrid M Dalsgaard, Mette K Yilmaz, Tone Fokstuen, Kjell M Tveit, Elin H Kurehttp://link.springer.com/content/pdf/10.1186/1471-2407-14-340.pdf, http://link.springer.com/article/10.1186/1471-2407-14-340/fulltext.html, http://link.springer.com/content/pdf/10.1186/1471-2407-14-340
European Journal of Cancer Supplements10.1016/s1359-6349(05)80897-3200532168601 ORAL Infusional 5-fluorouracil/folinic acid plus oxaliplatin (FUFOX) versus capecitabine plus oxaliplatin (CAPOX) as first line treatment of metastatic colorectal carcinoma (MCRC): results of the safety and efficacy analysishttps://api.elsevier.com/content/article/PII:S1359634905808973?httpAccept=text/xml, https://api.elsevier.com/content/article/PII:S1359634905808973?httpAccept=text/plain